Combined PET/CT Imaging for the Early Detection of Ocular Melanoma Metastasis Compared to CT Scanning Alone

The recruitment status of this study is unknown because the information has not been verified recently.
Verified February 2009 by University of California, Los Angeles.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
University of California, Los Angeles
ClinicalTrials.gov Identifier:
NCT00351728
First received: July 12, 2006
Last updated: June 17, 2010
Last verified: February 2009
  Purpose

Patients diagnosed with ocular melanoma consent to participate in the study. Combined PET/CT scans of the whole body are performed at baseline, three months later, and six months after that for a total of three combined scans in the first year. Subsequently, these combined scans will be performed at 6-monthly intervals for a total of two combined scans per year.


Condition
Ocular Melanoma
Choroidal Melanoma
Uveal Melanoma

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective

Resource links provided by NLM:


Further study details as provided by University of California, Los Angeles:

Estimated Enrollment: 250
Study Start Date: June 2006
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

choroidal melanoma patients

Criteria

Inclusion Criteria:

  1. Patients with a diagnosis of ocular melanoma (a pigmented malignant tumor) involving the choroid and/or ciliary body (the blood vessel layer in the back of the eye and/or the part of the eye behind the iris).
  2. Patients 18 years of age or older.
  3. Patients able to give informed consent.

Exclusion Criteria:

  1. Patients who refuse to participate in the study.
  2. Patients who are unable to cooperate with or cannot undergo PET/CT scanning.
  3. Patients who will be moving out of the area of UCLA during the ten years of this study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00351728

Contacts
Contact: Tara A. McCannel, M.D., Ph.D. (310) 206-7487 tmccannel@jsei.ucla.edu

Locations
United States, California
Jules Stein Eye Institute Recruiting
Los Angeles, California, United States, 90095-7000
Contact: Sandy Yin, M.S.    310-206-7484    yin@jsei.ucla.edu   
Sponsors and Collaborators
University of California, Los Angeles
Investigators
Principal Investigator: Tara A McCannel, MD, PhD Jules Stein Eye Institute, UCLA
  More Information

No publications provided

Responsible Party: Tara McCannel, M.D., Ph.D., University of California, Los Angeles
ClinicalTrials.gov Identifier: NCT00351728     History of Changes
Other Study ID Numbers: UCLA IRB #05-04-016
Study First Received: July 12, 2006
Last Updated: June 17, 2010
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Eye Neoplasms
Melanoma
Uveal Neoplasms
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Nerve Tissue
Nevi and Melanomas
Neoplasms by Site
Eye Diseases
Uveal Diseases

ClinicalTrials.gov processed this record on August 01, 2014